003520 — Yungjin Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Yungjin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	208,464	196,067	218,381	234,902	252,040
Cost of Revenue
Gross Profit	73,463	57,936	64,734	72,121	80,349
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	208,094	209,944	239,858	235,780	245,199
Operating Profit	370	-13,877	-21,477	-877	6,841
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	241	-14,144	-22,813	-3,918	2,887
Provision for Income Taxes
Net Income After Taxes	-133	-11,582	-21,961	-3,876	1,233
Net Income Before Extraordinary Items
Net Income	-133	-11,582	-21,961	-3,876	1,233
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-133	-11,582	-21,961	-3,876	1,233
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.6	-62.8	-68.1	-5.88	11.3
Dividends per Share